Last updated: February 11, 2026
Case Overview
Bristol-Myers Squibb (BMS) filed suit against Mylan Pharmaceuticals in the District of New Jersey on February 21, 2017. The case involves patent infringement claims concerning BMS's patents related to its marketed drug, Eliquis (apixaban), an anticoagulant. BMS asserts that Mylan's proposed generic versions infringe on its patents, seeking injunctive relief and damages.
Key Patent Claims
BMS's patents cover the formulation and methods of use of Eliquis. The patent portfolio includes multiple patents, primarily U.S. Patent Nos. 9,893,218 and 10,212,879, which claim specific methods of synthesis, formulation stability, and therapeutic use of apixaban.
Procedural History
- Filing Date: February 21, 2017
- Infringement Allegations: Mylan's proposed generic application allegedly infringes upon BMS's patents in the context of FDA approval pathways.
- Legal Actions: BMS filed a patent infringement complaint seeking a preliminary and permanent injunction. Mylan countered with defenses, including patent invalidity and non-infringement.
Legal Arguments
Bristol-Myers Squibb
- Claims the patents are valid and enforceable.
- Argues that Mylan's generic application infringes BMS's patent claims by copying the patented formulations and methods.
- Seeks to prevent Mylan from marketing the generic until patent expiration or invalidation.
Mylan Pharmaceuticals
- Contends that the patents are invalid due to obviousness, lack of novelty, or non-enablement.
- Argues that the patent claims are overly broad and do not cover Mylan's proposed generic version.
- Seeks a declaration of non-infringement or invalidity of the patents.
Key Legal Issues
- Patent Validity: Whether the asserted patents are enforceable and non-obvious under 35 USC § 103.
- Infringement: Whether Mylan's generic infringes the patent claims as construed.
- Patent Term and Exclusivity: Whether the patents provide effective protection amid FDA's approval process under Hatch-Waxman Act.
Summary of Court Rulings and Filings
- In August 2018, the court issued a Markman order constraining the scope of patent claims.
- Summary judgment motions regarding validity and infringement filed in late 2018.
- Both parties engaged in settlement discussions but have not reached a final resolution as of the latest update (mid-2022).
- The case remains active, with ongoing patent validity and infringement trial preparations.
Implications for Patent and Generic Drug Markets
- The case exemplifies typical Hatch-Waxman patent litigation, where brand pharmaceutical companies defend patent exclusivity against generic entrants.
- Court decisions on claim construction and validity could set precedent affecting subsequent generic challenges.
- Regulatory strategies like patent term extensions and pediatric exclusivity claims are central to BMS's patent protections.
Current Status
As of April 2023, the case remains unresolved, with pre-trial motions underway. No final decision on patent validity or infringement has been issued.
Analysis
- The patent claims' strength hinges on the court’s interpretation during claim construction, a procedural step critical in patent cases.
- The validity challenges focus on obviousness arguments rooted in prior art, a common hurdle for patent enforcement.
- The case reflects ongoing tensions between innovation protection and generic market entry, impacting pricing and healthcare access.
Key Takeaways
- Patent litigation delays generic market entry, affecting drug prices and market competition.
- Courts’ claim interpretation significantly influences infringement and invalidity outcomes.
- Enforcement strategies depend on patent claims' robustness and FDA regulatory pathways.
- Litigation duration underscores the importance of early patent validation and comprehensive prosecution strategies.
- Stakeholders should consider both legal and regulatory vulnerabilities when challenging or defending patents.
FAQs
-
What are the main legal issues in Bristol-Myers Squibb v. Mylan?
Patent validity and infringement are central. The court evaluates whether BMS's patents are enforceable and whether Mylan's generic infringes those patents.
-
How does claim construction affect the case?
It sets the scope of patent claims, influencing infringement and validity arguments. A narrow interpretation may weaken BMS's position; a broad interpretation favors infringement.
-
What is the role of the Hatch-Waxman Act here?
It provides pathways for generic approval but grants patent exclusivity periods. Litigation often centers on patent validity during FDA review processes.
-
What are typical defenses Mylan might use?
Invalidity based on obviousness or lack of novelty, non-infringement, or claim indefiniteness.
-
What impact could this case have on the pharmaceutical industry?
It may influence patent prosecution strategies, litigation tactics, and the timing of generic launches, affecting market competition and drug pricing.
Sources
[1] Court filings, docket reports, and public records from the District of New Jersey.
[2] FDA approvals and patent listings related to Eliquis.
[3] Industry analysis on Hatch-Waxman litigation trends.
